Paul Bragan, senior partner at Wakefield Research argues how Covid-19 could lead to the pharmaceutical industry examining how clinical trials operate.
Change
By necessitating social distancing and limiting travel, the Covid-19 outbreak has interrupted many ongoing clinical trials, with over 400 suspended since March 1st.
To ensure the continuation of certain trials during the pandemic, both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) relaxed clinical trial regulations in March and stressed that patient monitoring, patient consultations, and confirming patient consent can all now be accomplished remotely.